# Sacituzumab Govitecan In TNBC

> **NCT04230109** · PHASE2 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 260 (estimated)

## Conditions studied

- Invasive Breast Cancer
- Triple Negative Breast Cancer
- ER-Negative Breast Cancer
- PR-Negative Breast Cancer
- HER2-negative Breast Cancer

## Interventions

- **DRUG:** Sacituzumab Govitecan
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04230109
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-14
- **Primary completion:** 2028-10
- **Final completion:** 2029-10
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2025-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04230109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04230109, "Sacituzumab Govitecan In TNBC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04230109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*